Black Titan (NASDAQ:BTTC – Get Free Report) is one of 48 publicly-traded companies in the “Services – Computer Programming And Data Processing” industry, but how does it compare to its rivals? We will compare Black Titan to similar companies based on the strength of its valuation, institutional ownership, profitability, earnings, risk, analyst recommendations and dividends.
Volatility & Risk
Black Titan has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Black Titan’s rivals have a beta of 0.68, suggesting that their average share price is 32% less volatile than the S&P 500.
Insider and Institutional Ownership
56.0% of shares of all “Services – Computer Programming And Data Processing” companies are owned by institutional investors. 0.7% of Black Titan shares are owned by insiders. Comparatively, 16.3% of shares of all “Services – Computer Programming And Data Processing” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation and Earnings
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Black Titan | $180,000.00 | -$4.71 million | -0.63 |
| Black Titan Competitors | $222.38 million | -$53.25 million | -9.08 |
Black Titan’s rivals have higher revenue, but lower earnings than Black Titan. Black Titan is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Black Titan and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Black Titan | N/A | -108.60% | -95.64% |
| Black Titan Competitors | -51.08% | -912.69% | -63.05% |
Analyst Ratings
This is a summary of current ratings and recommmendations for Black Titan and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Black Titan | 1 | 0 | 0 | 0 | 1.00 |
| Black Titan Competitors | 98 | 197 | 218 | 12 | 2.27 |
As a group, “Services – Computer Programming And Data Processing” companies have a potential upside of 113.06%. Given Black Titan’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Black Titan has less favorable growth aspects than its rivals.
Summary
Black Titan rivals beat Black Titan on 8 of the 13 factors compared.
Black Titan Company Profile
Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.
Receive News & Ratings for Black Titan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Titan and related companies with MarketBeat.com's FREE daily email newsletter.
